Cell Therapy News/Articles, page-15792

Hi Pickagoodone……no one really ‘advises’ in this forum because everyone’s circumstances are different.Many motives for a variety of agendas can be exposed however. But this is the biotech space…high risk high reward. Many anomalies are possible when navigating through regulatory hurdles. MESO has successfully navigated numerous ‘hurdles’ but hit a few too. The CLR was one that did set us back. Three years later….another go at jumping it to get Ryoncil across the line. Remember after a 9-1 vote of approval that wasn’t enough. Aduheim…..an AD drug received a 10-0 vote AGAINST approval from Adcomm yet the FDA APPROVED that drug ? We are tadpoles swimming with sharks. Any money you invest now is at risk so only use money that you are not likely to need in the short to medium term. Personally I’m feeling more positive this time for all the reasons mentioned in other posts but it is ‘crystal ball stuff’ until I see that approval in black & white.